OrbiMed’s SpringWorks Therapeutics SWTX Stock Holding History

OrbiMed’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-172,600	Closed	-$7.62M	–	117
2025 Q1	$7.62M	Buy	+172,600	New	+$7.95M	0.18%	70

Other funds holding SWTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

OrbiMed's SWTX Position: Q2 2025 in Review

OrbiMed sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 950,200 shares — an estimated $41.9M sold.

OrbiMed first reported a position in SWTX in Q3 2019 and held it in 23 quarters. The position peaked at $537M in Q4 2020. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

OrbiMed reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
OrbiMed sold 950,200 SpringWorks Therapeutics shares in Q2 2025, an estimated $41.9M.
OrbiMed first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 23 quarters.
OrbiMed's SpringWorks Therapeutics position peaked at $537M in Q4 2020.
222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.